B

    BioNexus Gene Lab Corp Common stock (BGLC)

    Official site

    BASIC MATERIALS • SPECIALTY CHEMICALS • NASDAQ

    $1.44
    -0.11 (-7.10%)

    Market Cap: $4.55M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$-0.12N/AN/ABeat+64.7%
    Mar 26
    		$-0.22N/AN/ABeat-649.7%
    Dec 25
    		$-0.52N/AN/ABeat-169.7%
    Sep 25
    		$-0.40N/AN/ABeat+46.6%
    Jun 25
    		$-0.34$0.00N/AMiss-401.7%
    Mar 25
    		$-0.03N/AN/ABeat+48.9%
    Dec 24
    		$-0.19N/AN/ABeat-211.1%
    Sep 24
    		$-0.75N/AN/ABeat+51.9%
    Jun 24
    		$0.11N/AN/ABeat+162.9%
    Mar 24
    		$-0.06N/AN/ABeat-23.1%
    Dec 23
    		$0.17N/AN/ABeat+261.1%
    Sep 23
    		$-1.56N/AN/ABeat-2807.5%
    Jun 23
    		$-0.18N/AN/ABeat-85.2%
    Mar 23
    		$-0.05N/AN/ABeat-497.5%
    Dec 22
    		$-0.11N/AN/ABeat-273.4%
    Sep 22
    		$-0.05N/AN/ABeat-125.8%
    Jun 22
    		$-0.10N/AN/ABeat-5788.2%
    Mar 22
    		$0.01N/AN/ABeat+5900.0%
    Dec 21
    		$0.06N/AN/ABeat+3025.0%
    Sep 21
    		$0.21N/AN/ABeat+1582.9%
    Jun 21
    		$0.00N/AN/ABeat-26.1%
    Mar 21
    		$0.00N/AN/ABeat+166.7%
    Dec 20
    		$0.00$0.00N/ABeat-80.8%
    Sep 20
    		$0.01$0.00N/ABeat+1466.7%
    Jun 20
    		$0.00$0.00N/ABeat+866.7%
    Mar 20
    		$-0.00$0.00N/AMiss+66.7%
    Dec 19
    		$0.01$0.00N/ABeat+1400.0%
    Sep 19
    		$-0.00$0.00N/AMiss+10.0%
    Jun 19
    		$-0.00$0.00N/AMiss+76.9%
    Mar 19
    		$-0.00$0.00N/AMiss-50.0%
    Dec 18
    		$-0.00$0.00N/AMiss-115.1%
    Sep 18
    		$-0.00$0.00N/AMiss+16.7%
    Jun 18
    		$-0.00$0.00N/AMiss-
    Mar 18
    		$-0.00$0.00N/AMiss-
    Dec 17
    		$0.01$0.00N/ABeat-
    Sep 17
    		$-0.00$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-1.14EV/EBITDA629.53x
    Price/FCF-4.95xFCF Yield-20.21%
    Profitability
    Profit Margin-82.40%Operating Margin-398.70%
    ROE-33.70%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-136.85x
    Current Ratio6.08xQuick Ratio5.28x
    Trading Statistics
    Beta2.19Avg Volume14.60K
    52-Week High$6.1052-Week Low$1.07

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.53
    SMA 20$1.55
    SMA 50$1.68
    SMA 200$2.59
    EMA 10$1.52
    EMA 20$1.54
    EMA 50$1.68
    EMA 200$2.48

    MACD

    Line: -0.04Signal: -0.05Hist: 0.00

    ADX

    ADX: 23.6+DI: 24.3-DI: 30.3

    Aroon & PSAR

    Aroon Up60.0
    Aroon Down20.0
    PSAR$1.79

    Bollinger Bands

    Upper Band$1.66
    Lower Band$1.45
    %B Position1358%(Upper)
    Band Width-0.03

    RSI (14-Day)

    Neutral
    41.0

    Momentum Oscillators

    Stoch %K40.1
    Stoch %D35.6
    Williams %R-68.8
    ROC (10d)-9.5%
    Momentum-0.15
    CCI (20d)-115.5
    MFI (14d)79.7

    Volatility Measures

    ATR (14d)$0.12(8.4%)
    StdDev (20d)0.05
    Hist Vol66.7%(High)

    Volume Flow

    VWAP$1.48
    OBV137.8M
    AD Line5.2B
    CMF (20d)-0.214

    Volume Metrics

    Avg Vol (20d)9.9K
    Vol Ratio0.0x(Low)
    VWMA (20d)$1.57

    Pivot Points

    R3$1.62
    R2$1.58
    R1$1.57
    Pivot Point$1.53
    S1$1.52
    S2$1.48
    S3$1.47

    Advanced Oscillators

    TSI-11.46
    Ultimate Osc41.4
    KST-32.27

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$76,156$22,842$483,760$2.54M$2.26M$2.14M$2.52M$2.63M$1.97M$2.38M$2.27M$2.55M
    Cost of Revenue$39,955$-3,111$437,888$2.17M$1.82M$1.77M$1.37M$2.05M$1.13M$1.99M$2.01M$2.20M
    Gross Profit$12,982$-790$-3,983$377,685$368,022$343,493$309,234$326,536$288,720$365,031$266,555$354,332
    Operating Expenses$348,219$597,386$1.17M$1.15M$1.19M$1.05M$1.68M$2.09M$759,657$404,968$-1,178,311$3.08M
    R&D$13,671$14,487$11,098$14,876$12,557$12,139$17,396$10,442$8,198$11,475$0$0
    SG&A$298,526$327,669$181,095$445,691$516,790$391,876$165,932$792,413$558,829$315,794$-1,983,222$3.08M
    Operating Income$-282,396$-540,490$-1,032,845$-702,509$-611,293$-618,418$-416,220$-1,337,622$259,168$-79,028$257,754$-2,528,512
    Interest Income$21,183$17,179$9,079$24,970$62,136$37,016$-145,531$143,614$158,269$128,895$0$0
    Interest Expense$4,055$3,085$3,272$6,482$4,879$4,909$5,812$6,193$4,480$4,661$4,183$4,259
    Income Before Tax$-286,451$-543,575$-1,036,117$-708,991$-616,172$-623,327$-422,032$-1,343,815$254,688$-83,689$253,571$-2,532,771
    Income Tax Expense$0$0$0$0$0$0$-40,565$1,555$55,584$-20,068$0$76,418
    Net Income$-286,451$-543,575$-1,116,365$-708,991$-616,172$-623,327$-629,393$-1,345,370$199,104$177,317$308,463$-2,609,189
    EBITDA$-227,565$-482,844$-984,691$-616,778$-491,994$-549,146$-356,554$-1,267,747$309,798$-8,242$448,639$-2,266,099
    EBIT$-273,957$-526,726$-1,027,889$-660,133$-533,727$-589,167$-399,579$-1,316,822$278,341$-37,828$448,639$-2,329,228
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BGLC

    News

    Nasdaq Firm Makes Historic Shift to Ethereum-Based Treasury

    BioNexus Gene Lab Corp., a Nasdaq-listed biotech firm, has become the first to implement an Ethereum-focused treasury strategy, following Ethereum's inclusion in the U.S. "Crypto Strategic Reserve." The company released a whitepaper detailing Ethereum's benefits as a financial infrastructure asset due to its liquidity, utility, and stability, influenced by Wyoming's blockchain-friendly regulations. This move comes as Ethereum experiences a market downturn, with on-chain data suggesting institutional accumulation at current prices.

    Yellow.com•8/15/26•
    Bullish

    BioNexus Gene Lab Corp (BGLC) director receives 32,258-share fully vested award

    BioNexus Gene Lab Corp (BGLC) director Yap Chee Keong was granted a fully vested stock award of 32,258 common shares on August 13, 2026. This award, valued at $1.55 per share, was for completed services under the 2025 Equity Incentive Plan and involved no cash consideration. Following this transaction, Yap Chee Keong directly holds 32,258 shares of BGLC.

    Stock Titan•8/15/26•
    Somewhat-Bullish

    BioNexus Gene Lab Corp (BGLC) CEO reports 338,709-share award and 11.5% stake

    BioNexus Gene Lab Corp (BGLC) CEO Su-Leng Tan Lee was granted 338,709 shares as a fully vested Other Stock-Based Award under the company’s 2025 Equity Incentive Plan for completed services. This award gives her beneficial ownership of approximately 11.5% of the outstanding common stock, valued at $1.55 per share for plan purposes, totaling $524,998.95. Tan Lee holds sole voting and dispositive power over these shares, which were issued without cash consideration and are subject to Regulation S transfer restrictions and a six-month resale compliance period.

    Stock Titan•8/15/26•
    Neutral

    BioNexus Gene Lab Corp (BGLC) grants CEO 338,709 fully vested shares

    BioNexus Gene Lab Corp (BGLC) announced that its CEO and director, Tan Lee Su-Leng, received a fully vested stock award of 338,709 common shares. These shares, granted under the company's 2025 Equity Incentive Plan for completed services, were valued at $1.55 per share based on the August 12, 2026 Nasdaq closing price. Following this transaction, the CEO directly holds 338,709 common shares.

    Stock Titan•8/14/26•
    Neutral

    BioNexus Gene Lab Corp (BGLC) CFO receives 96,774-share equity award

    BioNexus Gene Lab Corp (BGLC) CFO, Chong Set Fui, was granted 96,774 fully vested common shares on August 13, 2026, as an equity award under the company's 2025 Equity Incentive Plan. This award, valued at $1.55 per share, was for completed services and involved no cash consideration. Following this transaction, Chong Set Fui directly holds 96,774 common shares in the company.

    Stock Titan•8/14/26•
    Neutral

    Frequently Asked Questions About BGLC

    Does BGLC pay dividends?
    BioNexus Gene Lab Corp Common stock (BGLC) does not currently pay a regular dividend.
    What is BGLC's market cap?
    BioNexus Gene Lab Corp Common stock (BGLC) has a market capitalization of $4.55M with a current stock price of $1.44.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In